Background: Targeting Apolipoprotein E4 (ApoE4) represents a frontier in Alzheimer’s disease therapeutics. This study investigates the therapeutic potential of a nutraceutical panel (Polydatin, trans-resveratrol, luteolin, and PEA) by exploring their interaction with the ApoE4 EZ-482 cavity. Methods: Using a dual-platform docking strategy (SwissDock and Schrödinger Maestro) across three structural constructs. Results and Discussion: We identified the full-length protein (1–299) as the optimal target, showing a robust correlation between normalized docking scores (Spearman ρ = 0.79). Crucially, biophysical analysis via dynamic light scattering (DLS) revealed that the ApoE4–oxLDL complex exhibits a ζ-potential of −10.97 mV, a state prone to pathological aggregation. Luteolin and PEA effectively altered this electrostatic environment, inducing significant positive shifts to +2.15 mV and +1.05 mV, respectively. The alignment between computational rankings and experimental ζ-potential perturbations supports the predictive reliability of our model. These findings suggest that nutraceuticals can modulate the ApoE4–oxLDL biophysical profile and highlight that a full structural context is mandatory for developing effective ApoE4-targeted interventions.
Saraceno et al. (Fri,) studied this question.